Floatz logo

Therapeutic Asset Ratings

13,145 results matching 1 filter

91,565 assets7,904 sponsors3,128 indications
Methodology v0.2
AssetSponsorPhaseRating
sar447537
Alpha 1-Antitrypsin Deficiency
SanofiP2B (57)
sar447537
Pulmonary Emphysema
SanofiP2B (57)
Sar-Bispsma, Cu-64
Metastatic Prostate Carcinoma
Curium US LLCP2B (57)
Sargramostim
Inflammatory Breast Carcinoma
Academic and Community Cancer Research UnitedP2B (57)
Scib1
Melanoma
Scancell LtdP2B (57)
Selumetinib
Malignant Pancreatic Neoplasm
National Cancer Institute (NCI)P2B (57)
Semaglutide
Alcohol Abuse
Insel Gruppe AG, University Hospital BernP2B (57)
Semaglutide
Alcohol Dependence
Psychiatric Centre RigshospitaletP2B (57)
Semaglutide
Brain Disorder
Chinese University of Hong KongP2B (57)
Semaglutide
HIV Infectious Disease
National Institute of Allergy and Infectious Diseases (NIAID)P2B (57)
Setanaxib
Fibrotic Liver Disease
Calliditas Therapeutics Suisse SAP2B (57)
Setanaxib
Primary Biliary Cholangitis
Calliditas Therapeutics Suisse SAP2B (57)
Shr-2004
Venous Thromboembolism
Beijing Suncadia Pharmaceuticals Co., LtdP2B (57)
Simvastatin
Chemotherapy-Induced Toxicity
Indonesia UniversityP2B (57)
Simvastatin
Small Cell Lung Carcinoma
Shanghai Pulmonary Hospital, Shanghai, ChinaP2B (57)
Sirexatamab
Colorectal Adenocarcinoma
Leap Therapeutics, Inc.P2B (57)
Sirexatamab
Colorectal Cancer
Leap Therapeutics, Inc.P2B (57)
Sirexatamab
Metastatic Malignant Neoplasm In The Colon
Leap Therapeutics, Inc.P2B (57)
Sirolimus
Acute Myeloid Leukemia By FAB Classification
City of Hope Medical CenterP2B (57)
Sirolimus
Liver Disorder
Nottingham University Hospitals NHS TrustP2B (57)
Sirolimus
Precancerous Condition
City of Hope Medical CenterP2B (57)
Solriamfetol
Hypersomnia
Duke UniversityP2B (57)
Solriamfetol
Long COVID-19
Duke UniversityP2B (57)
Solriamfetol
Sleep Disorder
Duke UniversityP2B (57)
Sorafenib
Chronic Myeloid Leukemia
St. Petersburg State Pavlov Medical UniversityP2B (57)
Showing 3451 to 3475 of 13,145 assets
PreviousPage 139 of 526Next